Elevated level and activity of LDHA is observed in K562/MDR leukaemia cells, and oxamate (an LDHA inhibitor) not only inhibits glycolytic flux but also restores the sensitivity of K562/MDR cells to adriamycin by counteracting Akt/mTOR/c-Myc signaling (Zhang et al., 2017). Here, MYC is linked to leukemia.